Identifying Biomarkers in Alzheimer's Disease

Recruiting now

Conditions studied: Neuro-Degenerative Disease, Alzheimer Disease

In brief

Alzheimer's disease is a severe neurodegenerative disorder of the brain that is characterized by progressive loss of memory and cognitive decline. With the ageing population, AD is a major public health problem affecting nearly 35 million people worldwide with numbers projected to rise to 115.4 million by 2050. AD is the only cause of death among the top ten causes that has no prevention or cure . It is believed that novel treatment of AD needs to start early or even at the prodromal stage in order to be effective. Therefore, there is an urgent need to find accurate methods of early detection before patients with AD develop clinical dementia. This study aims to identify biomarkers for AD in local Chinese population. this study hypothesizes blood-based proteomics, retinal imaging, ASL-MRP and tau PET can improve the accuracy and staging of AD.

Key facts

Study ID

NCT05655650

Run by

Chinese University of Hong Kong

People needed

300

Starts

2018-09-01

Expected to finish

2030-12-31

Last updated by the study team

2022-12-19

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Chinese ethnicity
• [For dementia group, clinical diagnosis of "probable Alzheimer's disease" according to recommendation from the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA)

You may not qualify if…

• Clinical diagnosis of non-AD dementia
• contraindication for MRI or PET

Where it is running

• Chinese University of Hong Kong — Hong Kong, Hong Hong, Hong Kong (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.